MedTrace Logo

Utility Assessment of a Pharmacy-to-Dose Daptomycin

NCT05224687 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-02-04

No results posted yet for this study

Summary

A pharmacy-to-dose (PTD) service, also referred to as pharmacy-based dosing, describes an established practice where providers can consult pharmacists for the dosing of various medications. Consulted pharmacists develop a treatment regimen utilizing protocols that are evaluated and approved by the relevant multidisciplinary committees of an institution.

Delegating tasks of therapy monitoring and dose selection to pharmacists resolves providers from this burden and ensures necessary changes are not unnoticed. Daptomycin was a medication that our facility included in PTD because of the required adjustments for renal dysfunction, indication dependent dosing, and its impact on clinical outcomes.

In 2019, our institution approved a PTD daptomycin protocol which allowed pharmacists to select a dose based on provider-selected indications, patient renal function, and body mass index. Pharmacists were also authorized to order creatine phosphokinase (CPK) levels at baseline and every 7 days, if the patient remained on daptomycin. Rounding the dose to the nearest 50 mg or vial size, as deemed appropriate, was also allowed. Daptomycin was one antimicrobial to be added to our growing list of PTD-approved medications. As such, pharmacists were already well acclimated to PTD processes by the time daptomycin was approved for this service.

Conditions

  • Antibiotics Causing Adverse Effects in Therapeutic Use

Interventions

OTHER

Retroactive review of patient data of those receiving a dose of daptomycin

A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Ronda Akins, PharmD · Methodist Health System

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224687 on ClinicalTrials.gov